Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Other financing activities (2024 - 2025)

Historic Other financing activities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $2.4 million.

  • Prelude Therapeutics' Other financing activities fell 5911.24% to $2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.3 million, marking a year-over-year change of. This contributed to the annual value of $21.3 million for FY2024, which is 1667.32% down from last year.
  • Latest data reveals that Prelude Therapeutics reported Other financing activities of $2.4 million as of Q3 2025, which was down 5911.24% from $3.8 million recorded in Q2 2025.
  • Prelude Therapeutics' Other financing activities' 5-year high stood at $21.2 million during Q4 2024, with a 5-year trough of $2.4 million in Q3 2025.